Spots Global Cancer Trial Database for A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Official Title: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
Study ID: NCT04133636
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California San Francisco, San Francisco, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
University of Chicago, Chicago, Illinois, United States
Indiana University, Indianapolis, Indiana, United States
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Montefiore Medical Center, Bronx, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Mount Sinai Medical Center, New York, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
UZ Gent, Gent, , Belgium
UZ Leuven, Leuven, , Belgium
CHRU de Lille Hopital Claude Huriez, Lille, , France
C.H.U. Hotel Dieu - France, Nantes, , France
Hopital Saint Louis, Paris cedex 10, , France
Universitaetsklinikum Hamburg Eppendorf, Hamburg, , Germany
Universitatsklinikum Wurzburg, Wuerzburg, , Germany
Sheba Medical Center Tel Hashomer, Ramat Gan, , Israel
Tel-Aviv Sourasky Medical Center, Tel-Aviv, , Israel
VU Medisch Centrum, Amsterdam, , Netherlands
University Medical Center Groningen, Groningen, , Netherlands
King Faisal Specialist Hospital & Research Center, Riyadh, , Saudi Arabia
Clinica Univ. de Navarra, Pamplona, , Spain
Hosp. Clinico Univ. de Salamanca, Salamanca, , Spain
Contact Details
Name: Janssen Research & Development, LLC Clinical Trial
Affiliation: Janssen Research & Development, LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
